Eli Lilly and (LLY) Given Daily Media Sentiment Rating of 0.16
News headlines about Eli Lilly and (NYSE:LLY) have trended somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.4231167518584 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
- Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin (finance.yahoo.com)
- Insider Selling: Eli Lilly and Company (LLY) Major Shareholder Sells 200,000 Shares of Stock (americanbankingnews.com)
- NSAV Subsidiary Signs Major Agreement With Eli Lilly and Company (markets.financialcontent.com)
- Lilly Issues Guidance for 2018, New Drugs to Drive Top Line (zacks.com)
- Eli Lilly office block will add capacity for 500 new jobs in Cork (irishexaminer.com)
A number of equities analysts have recently issued reports on LLY shares. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group restated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $90.25.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the firm posted $0.88 EPS. Eli Lilly and’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts anticipate that Eli Lilly and will post 4.21 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.56%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 841,088 shares of company stock worth $72,120,286. 0.20% of the stock is currently owned by insiders.
WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/14/eli-lilly-and-lly-given-daily-media-sentiment-rating-of-0-16.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.